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and then diffuse to the active site of AT1 receptor. Thus, lipid bilayers are expected to be actively involved and
play a critical role in drug action. For this reason, the thermal, dynamic and structural effects of olmesartan
alone and together with cholesterol were studied using differential scanning calorimetry (DSC), 13C magic-
angle spinning (MAS) nuclear magnetic resonance (NMR), cross-polarization (CP) MAS NMR, and Raman
spectroscopy as well as small- and wide angle X-ray scattering (SAXS and WAXS) on dipalmitoyl-
phosphatidylcholine (DPPC) multilamellar vesicles. 13C CP/MAS spectra provided direct evidence for the
incorporation of olmesartan and cholesterol in lipid bilayers. Raman and X-ray data revealed how both
molecules modify the bilayer's properties. Olmesartan locates itself at the head-group region and upper
segment of the lipid bilayers as 13C CP/MAS spectra show that its presence causes signiﬁcant chemical
shift changes mainly in the A ring of the steroidal part of cholesterol. The inﬂuence of olmesartan on
DPPC/cholesterol bilayers is less pronounced. Although, olmesartan and cholesterol are residing at the
same region of the lipid bilayers, due to their different sizes, display distinct impacts on the bilayer's
properties. Cholesterol broadens signiﬁcantly themain transition, abolishes the pre-transition, and decreases the
membrane ﬂuidity above the main transition. Olmesartan is the only so far studied ARB that increases the
gauche:trans ratio in the liquid crystalline phase. These signiﬁcant differences of olmesartan may in part
explain its distinct pharmacological proﬁle.: +39 040 375 8029.
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Hypertension is a chronic medical condition, which affects
approximately one billion people worldwide [1,2]. The renin–
angiotensin aldosterone system (RAAS) modulates blood pressure
and it is the major system associated with hypertension. Many classes
of antihypertensive medication are developed to act on RAAS.
Angiotensin II receptor blockers (ARBs) have been designed to inhibit
the binding of angiotensin II (AII) onto the G-protein coupled AT1receptor, and consequently decrease blood pressure [3–6]. Apart from
complications such as stroke, ischemic heart disease, vascular
remodeling and diabetic nephropathy, AII is associated also with
inﬂammation, oxidative stress and cell growth [1,7–9]. Olmesartan
medoxomil (Fig. 1A) belongs to the antihypertensive class of ARBs.
This drug is an ester prodrug of the active metabolite (Fig. 1B), which
is deesteriﬁed in the gastrointestinal tract [10,11]. The IUPAC name of
this active metabolite olmesartan is 5-(2-hydroxypropan-2-yl)-2-
propyl-3-[[4-[2-(2H-tetrazol-5-yl) phenyl] phenyl] methyl] imidaz-
ole-4-carboxylic acid.
Olmesartan medoxomil is commonly prescribed with a thiazide
diuretic (in general, hydrochlorothiazide (HCT)) and/or a calcium
channel blocker to ameliorate its effect [12–14]. The Food and Drug
Administration (FDA) approved olmesartan medoxomil on April
Fig. 1. The chemical structures of (A) prodrug olmesartan medoxomil; (B) olmesartan; (C) DPPC; and D) cholesterol.
2996 D. Ntountaniotis et al. / Biochimica et Biophysica Acta 1808 (2011) 2995–30062002, which was the seventh drug in the class of ARBs [15]. It has been
marketed as an antihypertensive drug in United States, Japan and
European countries [16]. The most recent approval by FDA was
announced on July 2010 for Tribenzor (olmesartan medoxomil,
amlodipine, hydrochlorothiazide), a new three-in-one combination
product for the treatment of hypertension, which contains an ARB, a
calcium channel blocker and a diuretic [17]. Although olmesartan
belongs to ARB class, it is proposed that its pharmacological proﬁle is
distinct from the others. Generally, not only pharmacological
similarities but also differences are observed among different ARBs
[11,18].
In this study, liquid and solid state nuclear magnetic resonance
(NMR), differential scanning calorimetry (DSC), Raman spectroscopy
as well as small- and wide angle X-ray scattering (SAXS, WAXS) were
applied to investigate the thermal, dynamic and structural properties
of olmesartan in dipalmitoyl-phosphatidylcholine (DPPC) bilayers in
the absence and presence of cholesterol.
In our previous studies we have put forward a two-step model in
which the AT1 prototype antagonist losartan ﬁrst inserts into the
bilayer core and diffuses towards the active site (ﬁrst step), and then
anchors to the active site (second step) [19]. As a continuation of ourstudies we are now examining and comparing the effects of AT1
antagonist olmesartan with losartan and other AT1 antagonists in
liposomal formulations to reveal their role in distribution and
eventually try to explain their drug efﬁcacies.
In this work, multilamellar vesicles (MLVs) of dipalmitoyl-
phosphatidylcholine (DPPC) (Fig. 1C) formed in excess of water
were used to model the plasma membranes of vasculature. Note, that
saturated phosphatidylcholines are themost abundant lipid species in
the plasma membrane of vasculature (40–65%) [20].
In the past DPPCMLVs have been extensively used in NMR andDSC
experiments to study the interactions of lipid-soluble drugs with
biological membranes as the main phase transitions occur at
convenient temperatures and are close to physiological ones [21–
26]. Cholesterol (Fig. 1D) is a major component of the cell plasma
membrane and its role is essential to establish proper membrane
permeability and ﬂuidity as well as to interfere with drug action [27–
29].
The aim of this research work is to study olmesartan–lipid
interactions in a temperature range from 20 °C up to 50 °C covering
all mesomorphic phases. DSC experiments using samples with
different molar ratios (olmesartan:phospholipid) were prepared.
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bilayers were formulated by adding different concentrations of the
drug. The idea behind the use of cholesterol is to simulate closer the
membrane lipidic environment.
The expected insight into the studied biomimetic systems is
manifold due to the given set of complementary methods applied.
Brieﬂy, DSC provides valuable information on the thermal modiﬁca-
tions that are caused by the presence of drugs in the membrane [26].
Performed solid state NMR experiments included 13C magic angle
spinning (MAS) and 13C cross polarization/magic angle spinning
spectroscopy (CP/MAS). These techniques offer useful information for
the dynamic changes that drugs cause when they are incorporated in
the lipid bilayers [30–33]. Typical observations are related with
chemical shift or intensity changes of various key atoms which are
partitioning in the membrane. Chemical shift changes are further
associated with phase transition properties of the membrane bilayer.
Moreover new peaks arise because of the presence of the drug [27].
Raman and X-ray diffraction experiments provide complementary
structural information, for instance regarding interdigitation effects of
the molecules in lipid bilayers [34]. All together, these techniques
characterize the properties of olmesartan especially in comparison
with other AT1 antagonists which were studied in our laboratory. On
these grounds, also the distinct pharmacological similarities and
differences of olmesartan to other ARBs are highlighted.
2. Materials and methods
2.1. Materials
Olmesartan was kindly donated from Daiichi Sankyo Pro Pharma,
Japan. Dipalmitoyl-phosphatidylcholine was purchased from Avanti
Polar Lipids Inc. (Alabaster, AL). Cholesterol and methanol were
purchased from Sigma Aldrich (St. Louis, MO).
2.2. Methods
2.2.1. Differential scanning calorimetry
Toprepare the samples forDSCexperiments, appropriate amountsof
DPPC, olmesartan and cholesterol, diluted in chloroform/methanolwere
mixed, dried under streamof argon and then stored under high vacuum
overnight. Distilled and deionized water was added to the dried
mixtures of DPPC–olmesartan and DPPC–cholesterol–olmesartan to
produce a 50% (w/w) mixture/water preparation (or water/lipid molar
ratio ranging from 41 to 52 depending on the mixture). The samples
were transferred to stainless steel capsules obtained from Perkin-Elmer
and sealed. Thermal scans were obtained on a Perkin-Elmer DSC-7
instrument (Norwalk, CT). All sampleswere scanned from10 to 60 °C at
least three times until identical thermal scans were obtained using a
scanning rate of 2.5 °C/min. The temperature scale of the calorimeter
was calibrated using indium (Tm=156.6 °C) and DPPC bilayers
(Tm=41.2 °C). The following diagnostic parameters were used for the
study of drug to membrane interactions: Tm (maximum position of the
recorded heat capacity), Tonset (the starting temperature of the phase
transition) and ΔTm1/2 (the full width at half maximum of the phase
transition), and the respective parameters concerning the pre-transi-
tion. An empty pan for the base line and a sample containing double
distilled water were run for the temperature range of 10–60 °C as a
reference for the background. This background was subtracted from
each thermal scan of the samples. The area under the peak, represents
the enthalpy change during the transition (ΔΗ). The mean values of ΔΗ
of three identical scans were tabulated.
The drug concentrations used for the different experiments were
x=0.05 (5 mol% olmesartan) and x=0.20 (20 mol% olmesartan). For
ternary mixtures, a ﬁxed DPPC/cholesterol ratio was kept (15 mol%
cholesterol), and either 5 mol% olmesartan or 20 mol% olmesartan
were added.2.2.2. Solid state NMR
The procedure to prepare the samples for 13C MAS and 13C CP/MAS
spectroscopy was identical to that applied for DSC samples. Brieﬂy,
distilled and deionizedwater was added to the dried binarymixtures of
DPPC/olmesartan and ternarymixtures of DPPC/cholesterol/olmesartan
to produce a 50% (w/w) liposome dispersion. The samples were
transferred to 3.2 mmzirconia rotors. 13CNMRspectrawere obtained at
150.80 MHz with a 600 MHz Varian spectrometer (Palo Alto, CA). The
spinning rate used was 5 kHz. The experimental temperatures were
25 °C, 35 °C, and 45 °C for 13C CP/MAS experiments and 45 °C for the 13C
MAS measurement.
2.2.3. High resolution liquid NMR
The high-resolution NMR spectra were recorded on a Varian
DirectDrive 800 MHz spectrometer at 25 °C. Spectra were obtained
with 2 mg of sample dissolved in 0.7 ml CD3OD (Sigma Aldrich, St.
Louis, MO). Default parameters installed in the library of the
spectrometer were used. The 1H and 13C chemical shift assignments
were obtained in a standard way using DQF-COSY, TOCSY, NOESY,
HSQC, and HMBC 2D experiments. Spectra were collected in the phase
sensitive mode using the pulse sequences in the Varian library of
pulse programs. Spectra allowed the unambiguous assignment of
olmesartan.
2.2.4. Raman spectroscopy
Raman spectra were recorded with a Perkin-Elmer GX Fourier
Transform spectrometer (Shelton, CT). A diode pumped Nd:YAG laser
at 1064 nm (Norwalk, CT) was used as the excitation source. The
scattered radiation was collected at an angle of 180° with respect to
the incident beam. Spectra were recorded at a laser power of 400 mW
on sample with a resolution of 2 cm−1. To obtain a good signal-to-
noise ratio, 2500 scans were coadded for each spectrum. The
temperature was controlled using the high-temperature cell (CAL
3300, Ventacon Ltd, Winchester, UK). The intensity of a Raman band
was observed over a period of 15 min. Analysis of the spectra was
carried out using the Spectrum Software Version No. 3.02.01 (Perkin-
Elmer, Norwalk, CT). Raman spectra of the examined samples were
obtained in the frequency region of 3500–400 cm−1 and in the
temperature range 25 to 50 °C.
2.2.5. X-ray scattering experiments
Time resolved simultaneous small- and wide-angle X-ray scatter-
ing (SAXS and WAXS) experiments were carried out at the Austrian
SAXS beamline at ELETTRA, Trieste [35,36]. The 1D position sensitive
detector [37] for SAXS covered the s-range (s=2 sin(θ)/λ with 2θ
being the scattering angle and λ=1.54 Å the applied X-ray wave-
length) of interest from about 1/250 Å−1 to 1/12 Å−1. The WAXS
detector (same type) covered the s-range from 1/9.4 to 1/3.2 Å−1. The
angular calibration was performed with silver-behenate (CH3
(CH2)20–COOAg: d-spacing 58.38 Å [38]) for the SAXS regime, and
for the WAXS regime the diffraction pattern of p-bromobenzoic acid
was used as reference [39]. The lipid dispersion was measured in a
thin-walled 1 mm diameter quartz capillary in a steel cuvette (Anton
Paar, Graz, Austria), whichwas inserted into a brass block. This sample
holder block was in thermal contact with a water circuit, i.e. it was
connected to a water bath with a freely programmable control unit
(Unistat CC, Huber, Offenburg, Germany). In order to avoid air
convection at the capillary, the entrance and exit windows of the
block have been covered with a thin polymer ﬁlm. The temperature
was measured in the vicinity of the capillary in the sample holder
block with a Pt-element (100 Ω). Prior to the temperature scan, the
sample was equilibrated for a period of 10 min at 20 °C. Static control
experiments before and after the scans were taken with an exposure
time of 120 s. For the time resolved experiments the samples were
heated from 20 to 60 °C and back to 20 °C with a scan rate of 1 °C/min
taking every minute exposures with a duration of 15 s. During the
Table 1
Diagnostic parameters ΔH, Tonset, Tm and ΔTm1/2 of the DSC experiments.
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order to keep the radiation dosage in the samples as small as possible.DPPC/olmesartan
0 mol% olmesartan 5 mol% olmesartan 20 mol% olmesartan
Pre-
trans.
Main
trans.
Pre-
trans.
Main
trans.
Pre-
trans.
Main
trans.
ΔH (J/g) 6.3 41.8 5.5 43.0 3.2 42.7
Tm (°C) 37.6 41.2 37.0 41.6 31.9 41.2
ΔTm1/2 1.0 0.9 1.8 1.0 2.9 1.3
DPPC/cholesterol/olmesartan (cholesterol ﬁxed at 15 mol%)
0 mol% olmesartan 5 mol% olmesartan 20 mol% olmesartan
Main trans. Main trans. Main trans.
ΔH (J/g) 29.2 29.2 31.0
Tm (°C) 40.6 40.5 40.6
ΔTm1/2 1.0 1.1 1.22.2.5.1. X-ray data-analysis. In the time resolved X-ray scattering
experiments the ﬁrst order diffraction peaks of the different gel and
liquid crystalline phases (reﬂections with the highest intensity) were
used to derive the lattice spacings in the SAXS and WAXS regime,
respectively, by standard procedures as described in ref. [40,41].
Brieﬂy, after the raw data had been corrected for detector efﬁciency
and the background scattering both from water and the sample cell
had been subtracted, all Bragg peaks were ﬁtted by Lorentzian
distributions, and the diffuseWAXS contribution arising from the ﬂuid
chain packing with a Gaussian distribution. The ﬁttings were carried
out with home written procedures running under IDL 5.2 (Research
Systems, Inc., USA). Few static scattering patterns were analyzed by
ﬁtting the form factor contributions with a simple bilayer model
[42,43]. This model uses one Gaussian for the head-groups and
another for the hydrophobic core.3. Results
3.1. Differential scanning calorimetry
The progressive thermal effects of olmesartan in DPPC bilayers are
shown in Fig. 2. The major thermal changes of olmesartan are
observed on the pre-transition. Already at a low concentration of
5 mol%, olmesartan broadens and lowers the pre-transition temper-
ature (see Table 1). At a drug concentration of 20 mol% the pre-
transition is almost invisible, and also concerning the main transition
ΔTm1/2 is broadened and Tm lowered, although not very signiﬁcantly
(Table 1, Fig. 2). ΔH is not affected either at low or at high drug
concentrations (see also SF1).
The thermal effects of olmesartan on DPPC/cholesterol bilayers
(85:15 molar ratio) is shown in Fig. 2. At 15 mol% cholesterol is well
known to abolish the pre-transition of DPPC bilayers, and cholesterol
somewhat broadens the main phase transition and slightly decreases
Tm[44]. Moreover, it causes a signiﬁcant lowering of ΔΗ (Table 1). In
this case, the addition of olmesartan (5 mol%) appears to not modify
signiﬁcantly the thermal events. Thus, it does not cause any signiﬁcant
changes in Tm, ΔTm1/2 and ΔH (SF1).Fig. 2. DSC thermal scans for samples with different lipid/drug/sterol molar ratios. From
top to the bottom: DPPC 100%, DPPC/olmesartan (95:5), DPPC/olmesartan (80:20),
DPPC/cholesterol (85:15) [DPPC/cholesterol]/olmesartan (95:5), and [DPPC/cholesterol]/
olmesartan (80:20). The DPPC:cholesterol ratio for the two last samples is 85:15.3.2. 13C MAS and CP/MAS NMR spectroscopy
To obtain detailed local information on the incorporation of
olmesartan and cholesterol in the DPPC bilayers, we applied high-
resolution NMR spectroscopy using magic angle spinning without or
with cross polarization [45].
The thermal effects of olmesartan in DPPC bilayers alone or with
cholesterol or olmesartan or the mixture of cholesterol/olmesartan are
shown in Fig. 3 (see also SF2–SF5). Each spectrumwasdivided into three
regions, namely concerning the carbon atoms in the (i) hydrophobic
region (10–40 ppm), those in the (ii) glycerol and backbone region (40–
80 ppm) and in the (iii) esteriﬁed carbonyls (near 170 ppm).
3.2.1. Hydrophobic region
The chemical shift decreases (upﬁeld effect), when DPPC bilayers
undergo the transition from the lamellar gel phase Lß′ (25 °C) towards
the ripple phase Pß′ (35 °C) and lamellar liquid crystalline phase Lα
(45 °C) (Table 2). This is due to the strong trans:gauche isomerisation
effects observed especially in the turnover to the Lα phase. For
example, we detected an upﬁeld change between 0.2 and 2.2 ppm for
(CH2)′10 , C-14′, C-15′ and C-16′ signifying the same trend and
different extent of upﬁeld effect of the carbons that constitute the
hydrophobic region. Upﬁeld effect (0.2–1.8 ppm) was also observed
in DPPC/cholesterol and DPPC/olmesartan bilayer (0.2–2.1 ppm)
samples [46,47].
3.2.2. Head-group region
Smaller changes were observed for the four preparations used in our
experiments indicating that head-group conformational changes from
gel to liquid crystalline phase are less pronounced compared to that
observed in the hydrophobic region (Table 2). The effect of cholesterol
or olmesartan has been examined in the head-group region by
comparing the chemical shifts of the lipid bilayers in the absence and
presence of cholesterol or olmesartan at identical temperatures.
Chemical shifts of DPPC/olmesartan were almost identical with those
of DPPC/cholesterol preparation. Thus, olmesartan exerts the same
effect as cholesterol in this head-group region. In addition, the effect of
cholesterol or olmesartan was less pronounced than that observed in
the hydrophobic region. To study the combined effect of cholesterol and
olmesartan, the preparation DPPC/cholesterol/olmesartan has been
compared with those of DPPC/cholesterol and DPPC/olmesartan. The
chemical shifts of all three preparations are almost identical, indicating
that combined effect of olmesartan with cholesterol is identical to those
of cholesterol or olmesartan alone.
3.2.3. Glycerol backbone region
A downﬁeld shift (b0.11 ppm) was observed during the phase
transition from the gel to liquid crystalline state indicating its
Fig. 3. 13C CP/MAS spectra at 45 °C for DPPC; DPPC/cholesterol (85:15); DPPC/olmesartan (80:20); and [DPPC/cholesterol]/olmesartan (80:20).
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DPPC, DPPC/cholesterol, DPPC/olmesartan. For the DPPC/cholesterol/
olmesartan sample a downﬁeld effect was already eminent in the
ripple phase (N0.2 ppm) (Table 2).
3.2.4. Carbonyl region
The resolution for C-1′ in the four preparations was not sufﬁcient
to follow the chemical shift changes during the phase transition
(Table 2). In DPPC bilayers for C-2′, a biphasic effect was observed, i.e.
a downﬁeld effect in the ripple phase and an upﬁeld effect in the
liquid crystalline phase. For C-3′ a progressive upﬁeld effect wasTable 2
Observed chemical shifts for DPPC carbons in 13C MAS and 13C CP/MAS experiments.
T
(°C)
Sample
C-1 C-2 C-3 C-1′,
C-1″
C-2′,
C-2″
13C MAS
45 DPPC 63.80 71.41 64.41 174.02 34.81
DPPC/cholesterol 63.88 71.45 64.53 174.19
+174.00
34.93
DPPC/olmesartan 63.85 71.44 64.48 174.13 34.89
(DPPC/cholesterol)/olmesartan 63.87 71.45 64.51 174.10
+173.92
34.89
13C CP/MAS
25 DPPC – 71.22 64.38 172–175 34.98
DPPC/cholesterol – 71.22 64.48 172–175 35.15
DPPC/olmesartan – 71.28 64.46 172–175 35.11
(DPPC/cholesterol)/olmesartan 63.74 71.21 64.49 172–175 35.15
35 DPPC – 71.14 64.38 172–175 35.10
DPPC/cholesterol – 71.21 64.47 172–175 35.19
DPPC/olmesartan – 71.40 64.56 172–175 35.19
(DPPC/cholesterol)/olmesartan – 71.48 64.50 174.52 34.18
45 DPPC 63.77 71.37 64.49 174.03 34.81
DPPC/cholesterol 63.86 71.43 64.55 174.17 34.93
DPPC/olmesartan 63.84 71.43 64.57 174.13 34.89
(DPPC/cholesterol)/olmesartan 63.89 71.45 64.56 174.16 34.90eminent as the temperature increases reaching approximately 1 ppm
in the Lα phase, indicating that this carbon in the carbonyl region
behaves similarly to all other carbons belonging to the hydrophobic
region. Similar effects were observed for the DPPC/cholesterol sample.
For DPPC/olmesartan bilayers an upﬁeld effect was observed for
carbonyl groups, whichmeans an opposite trend in comparison to the
DPPC and DPPC/cholesterol samples. For C-3′ a progressive upﬁeld
effect was observed, and for C-2′, a biphasic effect was seen like in the
DPPC and DPPC/cholesterol samples. When both olmesartan and
cholesterol are incorporated in DPPC bilayers, a small downﬁeld effect
was observed for carbonyl groups and a small upﬁeld effect wasC-X
C-3′,
C-3″
(CH2)′10, (CH2)″10 C-14′,
C-14″
C-15′,
C-15″
C-16′,
C16″
N(CH3)3 C-2‴ C-1‴
25.86 31.10 32.83 23.41 14.49 54.89 66.82 60.21
26.04 31.51 33.00 23.54 14.55 54.93 66.84 60.28
25.94 31.18 32.92 23.51 14.62 54.93 66.86 60.28
25.90 31.48 32.96 23.50 14.50 54.92 66.85 60.27
26.72 33.25 34.22 24.45 14.65 54.76 66.63 60.22
26.82 33.26 34.26 24.48 14.70 54.79 66.66 60.26
26.82 33.31 34.31 24.55 14.77 54.82 66.67 60.28
26.90 33.37 – 24.55 14.69 54.83 66.69 60.29
26.37 33.11 – 24.25 14.60 54.79 66.69 60.20
26.46 33.10 – 24.29 14.65 54.92 66.81 60.33
26.41 33.19 – 24.30 14.67 54.91 66.83 60.33
25.46 32.99 – 24.29 14.66 54.90 66.80 60.32
25.85 31.06 32.79 23.39 14.49 54.86 66.81 60.19
26.02 31.43 32.97 23.53 14.55 54.93 66.85 60.27
25.94 31.16 32.91 23.51 14.60 54.93 66.87 60.27
26.01 31.43 32.94 23.52 14.56 54.94 66.87 60.28
Fig. 4. (A) I1090/I1130 vs. temperature plots for pure DPPC (squares), DPPC containing
x=0.20 of olmesartan (circles), DPPC/olmesartan with x=0.10 cholesterol (triangles
up), and DPPC containing x=0.10 cholesterol alone (triangles down). With the
same symbolic meaning as in panel A the (B) I2850/I2880 vs. temperature plots and
(C) I2935/I2880 vs. temperature are depicted.
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probed by comparing the DPPC and DPPC/cholesterol samples. Small
downﬁeld changes attributed to cholesterol were also observed in all
mesomorphic states for C-2′ and C-3′. DPPC/olmesartan chemical shifts
are almost identical to those of DPPC/cholesterol, suggesting that
olmesartan and cholesterol cause the same effect in this region. An
exception was observed in the ripple phase where the DPPC/olmesartan
sample showedanupﬁeld effect onDPPCbilayers,whileDPPC/cholesterol
displayed a downﬁeld effect.
3.3. Raman spectroscopy
Raman spectra of pure DPPC bilayers and in the presence of 20 mol%
olmesartan alone or with 10 mol% cholesterol were obtained in a
temperature range of 26–50 °C. The spectra were recorded in a range
of 400–3500 cm−1 (Fig. 4). The transition behavior was especially
characterized by the C\C and C\H stretching modes. In particular,
the C\H stretching bands at ~2850 cm−1 and ~2880 cm−1 have
been analyzed, which are assigned to symmetric and antisymmetric
stretching modes in the methylene groups (CH2) of the alkyl chains,
respectively, while the band at ~2935 cm−1 is correlated to the chain
terminal methyl C\H symmetric stretching mode [48,49]. Further,
spectral bands in the spectral region 1000–1200 cm−1 related to the
C\C stretching modes have been investigated [50]. The bands at
~1090 cm−1 and ~1130 cm−1 reﬂect the C\C stretching modes in
gauche and trans conformations, respectively. (For a recent overview
on Raman spectra of DPPC bilayers see ref. [51]).
3.4. X-ray scattering
In Fig. 5, an overview of all carried out time-resolved SAXS/WAXS
experiments is given. In the contour plots high scattering intensities
are color-coded with red and orange, while lower scattering
intensities are given in green and blue. In Fig. 5A the widely studied
phase behavior of DPPC bilayers [52], and the corresponding
structural changes are illustrated. Here, we shall repeat only brieﬂy
the phase sequence. From 20 to about 36 °C the lamellar gel phase
(Lβ′) is existent [53]. The chains are tilted with respect to the bilayer
plane with about 32° [54], and are packed in an orthogonal lattice
[55,56]. Thereafter, the stable ripple phase (Pβ′) gets induced at about
36 °C [57,58]. Due to additional freedom in chain rotation, the
hydrocarbon chains pack here on a hexagonal lattice. At about 42 °C
the chains melt and the lamellar liquid crystalline phase is observed
(Lα) [59]. Note, that the transition is not reversible, but in cooling
direction two ripple phases form: the stable and the so-called
metastable ripple phase (Pβ′ and Pβ′ mtstbl). The later phase has a
ripple repeat distance that is about two times as big as that of the
stable ripple phase [58,60]. Second, the Lβ′ phase is not readily formed
in cooling direction, but instead a lamellar phase with a pronounced
stacking disorder can be seen. Also the interaction of cholesterol with
phosphatidylcholine bilayers has been widely studied [27,44,61,62],
and the main thermodynamic events are shown in Fig. 5B. At 10 mol%
cholesterol content a part of the phospholipids change their original
conformation, i.e. cholesterol induces the so called liquid ordered
phase (lo). This phase coexists with both, the gel-phase and also with
the Lα phase. Since the lipids in the lo-state are free to diffuse laterally,
the membrane below Tm becomes more ﬂuid, but on the other hand,
since the lipids in the lo-state display an all-trans chain conformation
the gauche:trans ratio decreases above Tm.
Strikingly, as can be seen in the SAXS patterns of Fig. 5C, olmesartan
provokes in thegel phase regime theunbindingof bilayermembranes: it
does not form multilamellar, but unilamellar vesicles (see also Fig. 6,
bottom curve). The unbinding is most probably caused by electrostatic
repulsion (membrane undulation usually plays a minor role in the gel
phase). In the liquid crystalline phase instead, multilamellar vesicles are
again apparent. In contrast to the effect of olmesartan alone (Fig. 5C), theincorporation of olmesartan together with cholesterol in the DPPC
bilayers induces again multilamellar vesicles also in the gel phase
(Fig. 5D). In fact the phase behavior of DPPC/olmesartan/cholesterol
bilayers is very alike to DPPC/cholesterol system. This is obvious when
comparing panel B with panel D.
The temperature dependent lamellar repeat distance, d, and lipid
chain packing of the four studied samples is presented in Fig. 7. The d-
Fig. 5. Temperature scan of multilamellar vesicles basing on DPPC from 20 to 60 °C and back to 20 °C with 1 °C/min. Note, frame numbers 1 and 80 refer to 20 °C, and the maximum
temperature was reached at frame 40. (A) Pure DPPC vesicles under excess of water conditions, (B) multilamellar vesicles of DPPC/cholesterol (90/10 molar ratio), (C) vesicles
containing DPPC/olmesartan (80/20), and (D) vesicles composed of DPPC/cholesterol/olmesartan (70/10/20) were investigated. Horizontal dashed lines in panel C refer to extracted
X-ray scattering patterns shown in Fig. 6.
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phase are similar, i.e. the anomalous swelling behavior [63,64] in the
vicinity of the melting point are alike (Fig. 7A). The absolute d-valuesFig. 6. SAXS andWAXS patterns of vesicles containing DPPC/olmesartan (80/20 mol/mol)
at 20 (black line) and 60 °C (red line), respectively. The patterns refer to the temperature
scan depicted in Fig. 5C. The form factor scattering in gel-phase has been ﬁtted applying a
simple bilayer model (solid green line).though differ a bit: the biggest membrane repeat is found for ternary
lipid bilayers (66.6 Å at 50 °C), followed by DPPC/cholesterol (66.2 Å),
DPPC/olmesartan (65.8 Å), and ﬁnally completed by pure DPPC
bilayers (65.2 Å). The lipid chain packing gives a relative good
indication for the main transition temperature, Tm (Figs. 7B–D). The
melting point for DPPC alone and DPPC/olmesartan is determined
with theWAXS recordings to be at 42.5 °C, while for DPPC/cholesterol
and DPPC/olmesartan/cholesterol Tm is about 1 degree lower, i.e.
Tm=41.5 °C. Please note, that the absolute transition temperature for
the loss of long range order in the chain packing is about 1 °C higher as
expected from observed the chain melting transition temperature
obtained from the DSC measurements (cp. Table 1). This small
retardation in the structural rearrangements of chain packing is
probably due to the chosen scan rate of 1 °C/min. At scan rates of
0.1 °C/min and less, the thermal and structural events should
superimpose, see e.g. reference [65].
4. Discussion
4.1. Differential scanning calorimetry
The thermal behavior of olmesartan in lipid bilayers shows that
mainly the head-group region is affected. This conclusion is drawn,
because actually only the pre-transition gets abolished, i.e. the ripple
Fig. 7. (A) Lamellar repeat distance, d, as function of temperature for DPPC (black), DPPC/cholesterol (blue), DPPC/olmesartan (magenta), and DPPC/olmesartan/cholesterol bilayers.
(B, C, D) The nearest neighbor chain to chain distances derived from the ﬁrst order diffraction peaks in the gel phase, and rough distances determined from the position of the diffuse
scattering maximum in the liquid crystalline phase are displayed. Samples are the same as in Fig. 5.
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mismatch of projected head-group to lipid chain area gets reduced.
On the other hand, losartan has no signiﬁcant effect on themain phase
transition; deﬁnitely olmesartan does not increase ΔΗ. This is in
contrast to valsartan and losartan, were an increase in the main
transition enthalpy was accounted mainly to an increase in volume
expansion work during the main transition [19,66]. Thus, it appears
that olmesartan probably interacts on the head-group region and
upper segment of the alkyl chains, but less strongly with the
hydrophobic core of the bilayer as losartan and valsartan that have
been shown to induce at least partial chain interdigitation. Cande-
sartan, although showing similar thermal proﬁles with olmesartan,
does increase ΔΗ signiﬁcantly [67]. The fact that olmesartan did not
impose any ΔΗ increase, indicates that it induces no lipid interdig-
itation [33,68]. This is also conﬁrmed by the X-ray data as discussed
below.
The similarities and differences of olmesartan with other ARBs can
be interpreted as follows: both olmesartan and candesartan are
disturbing less the chain packing in the lipid bilayers, since they have
no extensive alkyl chains. Such an observation is in agreement with
reported results published recently by Makriyannis et al. [69] using
deuterium solid state NMR spectroscopy. However, such behavior
cannot be accounted just by examining their lipophilic proﬁle [70].
The thermal behavior of olmesartan in DPPC/cholesterol bilayers
provides less evidence that the drug molecule exerts its action on the
head-group. Since cholesterol by itself abolishes the pre-transition
any additional effect attributed to the drug olmesartan is obscured.
Even the presence of olmesartan at 20% does not cause any signiﬁcant
change in the main transition temperature and its width (Table 1).
However, it increasesΔH, although this increase is still lower than that
observed with DPPC bilayers alone (SF1).4.2. 13C MAS and CP/MAS NMR spectroscopy
13C CP/MAS spectra showed that the effect of cholesterol or
olmesartan was less pronounced in the head-group in comparison to
that exerted in the hydrophobic region. This is in agreement with the
Raman spectroscopy data as both cholesterol and olmesartan affected
signiﬁcantly the gauche:trans ratio. The downﬁeld effect exerted by
both cholesterol and olmesartan at glycerol backbone and carbonyl
regions indicate that both molecules affect this region.
13C NMR spectroscopy allows comparing the dynamic effects of
olmesartan with cholesterol and other ARBs. The results attributed to
cholesterol or olmesartan are summarized (see ST1 and ST2). Due to
the low intensity of the olmesartan peaks, they are not evidently
visible in Fig. 3 and SF2–SF4. In terms of peaks attributed to
cholesterol, the following observation can be made: almost all peaks
attributed to the four rings and alkyl chains are eminent and grow in
intensity as the temperature increases. This shows that cholesterol is
embedded in the membrane with considerable motion. The most
prominent chemical shift changes relatively to those observed in solid
cholesterol are those referring to the A-ring (see Fig. 1D). This
indicates that the cholesterol A-ring is in spatial vicinity of the polar
part of the lipid bilayers (i.e. C1 differs 1.2–1.3 ppm from the
reference).
In contrast to cholesterol, only few olmesartan peakswere observed,
reﬂecting the rigidity of the molecule in lipid bilayers. The peaks
attributed to the aromatic rings are characterized as broad and of low in
intensity. Interestingly, this is observedboth, in 13CCP/MAS and 13CMAS
experiments indicating that the small intensity and broad peaks
observed are not due to the insufﬁcient cross polarization. The fact
that in the 13C MAS experiments the peaks are barely seen, is attributed
to the low sensitivity of this experiment as compared to the cross
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chain of olmesartan. The above observations show that olmesartan has
different dynamic properties in the lipid bilayers than cholesterol. Two
plausible explanations can be given: (a) the aromatic part of olmesartan
is more rigidiﬁed in the bilayer core when compared to cholesterol
and/or (b) a smaller amount of drug is incorporated in the lipid bilayers.
This second explanation is in accordance with DSC data which show
no additional thermal effect of the drug and X-ray results which give
a hint for a reduced drug-membrane afﬁnity in the gel phase when
DPPC/cholesterol bilayers are applied.
In comparison to our previous studies [19] using solid state 13C
MAS for DPPC/losartan preparation some distinct differences can be
realized. Losartan aromatic peaks were prominent, easily to be
identiﬁed and sharper. Thus, it appears that biphenyltetrazole ring
of the two AT1 antagonists shows distinct mobility. Losartan's
biphenyltetrazole is more mobile than that of olmesartan. This
explains the differential thermal properties of olmesartan and
losartan. Losartan anchors with tetrazole ring in the head-group
region (note, that this drug is provided as a salt and has negative
charge on the tetrazole), while the alkyl chain is more ﬂexible in the
lipidic core. This topographical position in lipid bilayers is reﬂected as
abolishment of the pre-transition temperature and lowering of the
main phase transition already at low losartan concentrations.
Olmesartan does not have such a strong anchoring, although clearly
is situated in the vicinity of the head-group. This is reﬂected in the fact
that the pre-transition does not get completely abolished and it rather
increases the main phase transition temperature. Nevertheless, it ﬁts
and packs properly in lipid bilayers.
The signiﬁcance of the aromatic packing was shown also in our
previous work. We showed that membranes restrict the motion of a
pair of inactive–active pair of steroids Δ16-alphaxalone–alphaxalone
respectively in a different manner [71]. Interestingly, we have also
shown that the inactive analog was not incorporated in high degree in
membranes in contrast to the fully incorporation of the active analog
[72]. We have also shown that the aromatic part of the inactive analog
Me-Δ8-THC was more mobile than its active psychomimetic analog
Δ8-THC [32,33]. These results show that solid-state NMR is capable of
differentiating between the effects of structurally very similar
compounds. Such observation is in agreement with the conclusions
by Santos et al. who observed different effects in the case of
structurally related tricyclic antidepressants desipramine and imip-
ramine [73].
4.3. Raman spectroscopy
Intramolecular trans–gauche conformational changes within the
hydrocarbon chain region can be monitored directly by the intensity
ratio I1090/I1130. This peak height intensity ratio allows the direct
comparison of the bilayers order–disorder transitions between
liposome preparations without or with drug incorporation [74]. In
Fig. 4A the changes in I1090/I1130 intensity ratio in pure DPPC, DPPC/
cholesterol as well as DPPC/olmesartan and DPPC/olmesartan/
cholesterol bilayers are presented. The transition temperatures
compare well to the results found from the calorimetric measure-
ments and are clearly indicated. DPPC shows a strong ΔΙ increase
across the gel to liquid crystalline phase (ΔΙ=1.29–0.71=0.58,
which means an increase of 81.2%). This increase is smaller with
cholesterol indicating especially its condensing effect in the liquid
crystalline phase (0.78 to 0.90 or 15.5%). On the other hand,
olmesartan induces an increase of the gauche-trans ratio across the
gel to liquid crystalline phase transition: ΔI increases from 0.89 to
about 1.71 (ΔI=0.83), which means an increase of about 93%.
Cholesterol together with olmesartan causes a further increase during
the main phase (ΔΙ=2.12–0.96=1.1 (115.7%)). These results signify
that both olmesartan and olmesartan/cholesterol mixture increase
entropy changes during the main phase transition.Interestingly, the presence of losartan, valsartan or candesartan
lower the ΔI values [66,75] which is opposite to the effect of
olmesartan. Thus, in DPPC bilayers the chain mobility changes
decrease by the formerly studied three AT1 antagonists, while it
increases for olmesartan.
The most intense bands in the Raman spectrum of lipid samples
are given in the methylene C\H stretching mode region 2800–
3000 cm−1, which are commonly used to monitor changes in the
lateral packing properties and mobility of the lipid chain in both gel
and liquid crystalline bilayer systems [76]. In particular, the analysis of
the symmetrical and antisymmetrical methylene stretching bands
allows investigating the thermotropic phase behavior of lipids. Levin
and co-workers were the ﬁrst to introduce the intensity ratio of these
two bands I2850/I2880 as an order parameter [77]. This ratio describes
the main change occurring in the hydrocarbon-chain region of the
lipids and corresponds to intermolecular interactions among aliphatic
chains. It is sensitive to subtle changes in conformational order from
rotations, kinks, twists and bends of the lipid chains [78]. Alike to the
ratio I1090/I1130 the presence of olmesartan or olmesartan/cholesterol
causes signiﬁcant increase also in the I2850/I2880 meaning that both,
drug alone or in the present of cholesterol cause disorder in the lipid
bilayers (Fig. 4B). The same applies for the ratio I2935/I2880 (Fig. 4C).
Thus, consistently the three ratios show that olmesartan causes
ﬂuidization of the lipid bilayers which is strengthened by the
incorporation of cholesterol.
Other characteristic band alterations in the liquid crystalline phase
provide evidence for the incorporation of olmesartan in the
monolayer leaﬂets of the DPPC membrane. First, the band at
715 cm−1 which corresponds to C\N symmetric stretching vibration
of the polar head-group [79] of DPPC bilayers shows a downshifting of
1 cm−1 in the examined temperature range, when olmesartan is
incorporated in lipid bilayers (data not shown). This is the opposite
effect to that observed for candesartan [74], losartan [19,34,80] and
valsartan [75], but similar to the effects observed for dipeptide and
non-steroidal anti-inﬂammatory molecules [81,82] which bind only
loosely to the head-group area. Last, the presence of olmesartan in
DPPC/cholesterol bilayers causes an upshifting of the 715 cm−1 band
and the temperature proﬁle of this band behaves like DPPC bilayers
alone. These results show that cholesterol and olmesartan have an
opposite effect on head–group interactions.
Second, the band at 1294 cm−1 which corresponds to (CH)2
twisting vibration of the acyl chains [83] of DPPC bilayers shows an
upshifting of 1 cm−1 in the examined temperature range, when
olmesartan is present in DPPC bilayers. Cholesterol has a synergistic
effect, since it shifted this band to even higherwavenumbers (data not
shown). These results are in accordance with the three ratios (Fig. 4),
that conﬁrm an increase of the lipid bilayer's ﬂuidity with the
presence of olmesartan, which is even enhanced when cholesterol is
added.
Third, a new peak at 1024 cm−1 which corresponds to the
“breathing” of the aromatic rings of olmesartan clearly identiﬁes the
incorporation of it in DPPC bilayers (data not shown) in accordance
with solid state NMR data (see ST2) [84].
4.4. X-ray scattering
The integration of olmesartan to pure DPPC bilayers causes in the
gel-phase the unbinding of membranes (Fig. 5C). Asmentioned above,
this is understood to be due to the electrostatic repulsion, which is
caused by the membrane surface charges in the presence of
olmesartan. Olmesartan has a rather low pKa value of 4.3 [85], and
therefore a high ratio of ionized form is likely to show up at pH 7.
Please note, that a similar unbinding behavior has been observed also
for losartan loaded PC-vesicles (data not shown), which has an even
lower pKa value of 3.15 [86]. Nevertheless, increasing the temperature
and passing the melting point, the membranes rebind again, i.e.
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the electrostatic repulsion decreases above Tm. A possible explanation
lies in the increase of the area per molecule (about 30%), which in turn
would lead to a decrease in the surface charge density, and hence to a
reduction in the electrostatic repulsion, if the olmesartan concentra-
tion in the bilayers remains the same. Remarkably, as we could show
recently [75], also the DPPC/valsartan bilayers exhibit a reduction of
the overall repulsion force above Tm, although the effect was not as
strong. This is plausible though, given the higher pKa value of 4.9 for
valsartan [86]. Nevertheless, other effects like a different penetration
depths of olmesartan in the ﬂuid bilayer and/or a diminished
olmesartan partitioning in the ﬂuid bilayers could also decrease the
electrostatic repulsion force. However, the transition is reversible
(Fig. 5C), whichmakes a strong expulsion of olmesartan from the ﬂuid
bilayers less probable. Nevertheless, further analysis of the scattering
curve at 20 °C (Fig. 6, bottom curve) reveals that olmesartan has no
big inﬂuence onto the chain region of the DPPC bilayers, i.e. there is no
measurable effect on the bilayer thickness. We ﬁnd that the head-
group to head-group distance, dHH, is 44.6±0.4 Å, which compares
very well with the published value of 44.2 Å for pure DPPC bilayers
[59]. This is in contrast to other ARBs, which are able to induce at least
partial interdigitation in the gel-phase, which has for instance
recently been demonstrated for the action of valsartan on DPPC
vesicles [75]. As can be seen in theWAXS regime (Fig. 6, bottom right),
also the chain-packing remains unaltered: the underlying ortho-
rhombic lattice displays the typical sharp (20)-reﬂection (arrow)with
a d20-spacing of 4.27 Å together with the broader (11)-reﬂection
(arrow) with a d11-spacing of about 4.17 Å. This compares well to the
pure DPPC data from Sun et al. [56], who published the values
d20=4.244 Å and d11=4.182 Å for pure DPPC vesicles at 24 °C.
Completely different is the situation, when olmesartan is added to
DPPC/cholesterol bilayers (Fig. 5D). Here olmesartan does not induce
any unbinding of membranes. An explanation could be that the
afﬁnity of olmesartan for the DPPC/cholesterol bilayers is reduced as
compared to pure DPPC bilayers. This actually would also mean that
the electrostatic repulsion gets reduced in the ternary bilayer system.
Further, when comparing the overall lattice spacings (d-values) of
the DPPC/olmesartan/cholesterol and DPPC/cholesterol systems
(Fig. 7A), no big difference is seen over the whole temperature range.
This actually also supports the interpretation, that the afﬁnity of the
DPPC/cholesterol bilayers are not in favor for the olmesartan up-take.
The temperature dependent analysis of the chain packing (Figs.
7B–D) does not reveal any further surprises. In agreement with the
DSC data in the DPPC/cholesterol samples (Figs. 7B and D) the chain
melting transition temperature is reduced about 1 °C, while the
addition of olmesartan alone (Fig. 7C) does not change the Tm
(compare also DSC data, Table 1). This is readily understood, since
cholesterol in low concentrations can be considered as impurity in the
DPPC bilayers, and hence a lowering of the melting point is expected.
5. Conclusion
13C CP/MAS spectra provided direct evidence for the incorporation
of cholesterol and olmesartan in lipid bilayers as many peaks in the
spectra can be attributed to their presence. DSC, Raman spectroscopy
and X-ray diffraction data are in accordance with the NMR data, since
the presence of the cholesterol or olmesartan does modiﬁes some of
the observed key parameters of the lipid bilayers. X-ray diffraction
data demonstrate in addition that under neutral pH conditions a high
fraction of olmesartanmolecules are ionized (bilayer unbinding in the
gel-phase), and further we observed that the afﬁnity of olmesartan
for DPPC/cholesterol bilayers is reduced as compared to pure DPPC
bilayers. This might have important biological consequences in
the drug diffusion towards the active site of the receptor as it is
well known that cholesterol is one of the major constituent of lipid
bilayers.Olmesartan is most probably located at the head-group region and
upper segment of the membranes, because it does not affect
signiﬁcantly the chemical shifts of alkyl chain segment of cholesterol
in the DPPC/cholesterol/olmesartan bilayers. Thus, the effect of
olmesartan is restrained on the head-group, glycerol and carbonyl
region and upper segment of the alkyl chain region of the lipid
membranes.
Additional evidence that olmesartan mainly effects the head-
group region is given by the DSC results. Although olmesartan and
cholesterol are competing or residing at the same topographical
membrane region, due to their different sizes and ﬂexibility exert
different effects. While olmesartan affects signiﬁcantly only the pre-
transition, cholesterol not only abolishes the pre-transition, but also
exerts also signiﬁcant effects in the main transition (lowering its
cooperativity and decreasing the Tm).
Of great interest though is the fact that olmesartan shows distinct
dynamic properties in lipid bilayers which differ from other ARBs so
far studied. For example, in our previous work [75] we showed that
valsartan caused a decrease in the bilayer thickness due to partial lipid
interdigitation. Such an effect was not observedwith olmesartan as X-
ray diffraction data conﬁrmed a constant bilayer in the gel-phase.
Further, no indication for an olmesartan induced phase separation is
given as supported also by the DSC and Raman spectroscopy data.
In addition, valsartan and losartan cause differential modiﬁcations
in the thermal changes of lipid bilayers [67,75]. Valsartan and losartan
abolish the pre-transition already at low concentrations and cause a
signiﬁcant lowering of the main phase transition temperature.
Olmesartan, on the other hand, only at high concentrations afforded
the abolishment of the pre-transition and has no signiﬁcant effect on
the main phase transition temperature. Candesartan, losartan and
valsartan cause an increase in ΔΗ and of the trans:gauche ratio
[67,68,75], but although olmesartan causes a strong decrease in the
trans:gauche ratio, it does not affect ΔΗ signiﬁcantly. All these
differences propose a different mode of action of olmesartan when
it is incorporated in the lipid bilayers.
The emerging picture is that although all ARBs so far studied
appear to localize in the head-group regime, they affect differently
both the head-group and the alkyl chain region. Olmesartan causes
the least structural changes on the polar/apolar membrane interface
attributed probably due to smaller penetration depths in bilayers and
concurring aggregations in the water phase [87]. These associations
are, however, expected to be less effective in the liquid crystalline
matrix of the membranes, since at sufﬁcient concentrations the drug
succeeds to embed also in the upper hydrophobic core. Such
limitation in the effectiveness is not seen with losartan and valsartan.
Candesartan CV shows similar property with olmesartan in this
respect [67].
From this analysis it appears that each ARB molecule appears to
have its own ﬁngerprint regarding thermal and dynamic interac-
tions with lipid bilayers, even if all of them reside at the bilayer–
water interface. This explains their common site of action (i.e. AT1
receptor), but gives also a hint for their different pharmacological
properties. The different properties of ARBs provide an important
message. Lipid/ARB interactions might be the selective key, which
in the end determine the unique pharmacological response.
However, more studies starting from simple and then leading to
more complex biomimetic model systems are necessary to pin
down the individual functionalities of differently designed mem-
brane active drugs.
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